Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients

This study has been completed.
Sponsor:
Collaborator:
ALS Association
Information provided by (Responsible Party):
Kirsten Gruis, University of Michigan
ClinicalTrials.gov Identifier:
NCT01154283
First received: June 29, 2010
Last updated: July 9, 2013
Last verified: July 2013
  Purpose

The purpose of the study is to test whether noninvasive positive pressure ventilation (NIPPV) without expiratory positive airway pressure (EPAP) (inspiratory positive airway pressure (IPAP)-only) will result in an increase in patient usage of NIPPV compared with standard NIPPV. Secondarily, the investigators will assess measures of dyspnea, quality of life, patient satisfaction, and side effects.


Condition Intervention
Amyotrophic Lateral Sclerosis
Device: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Randomized Crossover Study of Standard, Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in Amyotrophic Lateral Sclerosis (ALS) Patients

Resource links provided by NLM:


Further study details as provided by University of Michigan:

Primary Outcome Measures:
  • Hours of NIPPV usage [ Time Frame: Assessed at 6 weeks ] [ Designated as safety issue: No ]
  • Hours of NIPPV usage [ Time Frame: Assessed at 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient satisfaction (Likert scale) [ Time Frame: Assessed at 12 weeks ] [ Designated as safety issue: No ]
  • Dyspnea (BDI/TDI scales) [ Time Frame: Assessed at 6 weeks ] [ Designated as safety issue: No ]
  • Dyspnea (BDI/TDI scales) [ Time Frame: Assessed at 12 weeks ] [ Designated as safety issue: No ]
  • Quality of life (EuroQol VAS) [ Time Frame: Assessed at 6 weeks ] [ Designated as safety issue: No ]
  • Quality of life (EuroQol VAS) [ Time Frame: Assessed at 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 17
Study Start Date: January 2008
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bi-level, standard, NIPPV
Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
Device: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Noninvasive positive airway pressure ventilation
Experimental: IPAP-only, NIPPV
NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
Device: Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Noninvasive positive airway pressure ventilation

Detailed Description:

Subjects will be randomized on a 1:1 basis to one of two groups differing in the sequence of NIPPV settings ((a) standard, Bi-level NIPPV followed by IPAP-only NIPPV or (b) IPAP-only NIPPV followed by standard, Bi-level, NIPPV). Subjects will then spend 6 weeks using the first NIPPV set-up before crossing over to the other NIPPV treatment for 6 weeks. At the beginning of the study, subjects will undergo approximately two hours of training and education by a respiratory therapist regarding proper use of the Viasys® Healthcare, Pulmonetic Systems, lap-top ventilators (LTV machine). They will be fitted with the appropriate NIPPV set-up. The patients will use the same mask interface with the study NIPPV machine that they were using with their NIPPV (bi-level positive airway pressure (BiPAP)) machine prior to study entry.

The patients will have two additional study visits after the consent/training session: one at the end of 6 weeks, after the first NIPPV treatment period (prior to crossing over to the second NIPPV treatment), and the second at the end of 12 weeks, after the second NIPPV treatment period.

NIPPV usage will be recorded as hours of use as measured objectively by the NIPPV machine hour meter. When the patient returns for his/her first study visit at the end of week six, the NIPPV machine hour meter will be recorded by the study investigator. By subtracting the hours recorded at the beginning of week two from the hours recorded at the end of week six, the NIPPV hours of usage for weeks two, three, four, five and six will be obtained. This same procedure will be repeated to record NIPPV hours of usage for the beginning of week eight and the end of week twelve to measure the hours of usage with the second NIPPV set-up for weeks eight, nine, ten, eleven and twelve. This allows study subjects one week to adjust to the new pressure settings of each treatment arm.

Dyspnea as measured by the baseline dyspnea index/ transition dyspnea index (BDI/TDI), and quality of life as measured by the EuroQol Visual analogue scale(VAS) will be re-administered at both 6 and 12 week study visits by study personnel. Lastly, patient preference of NIPPV treatment will be subjectively assessed at the 12 week study visit on a Likert scale (definitely first treatment, probably first treatment, no preference, probably second treatment, definitely second treatment).

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age greater than 18 years
  2. Definite or probable ALS by El Escorial criteria
  3. Maximal inspiratory force < 60 cm/H2O or FVC <50% predicted (American College of Chest Physicians' criteria for initiating NIPPV)
  4. Patients must have used NIPPV (typically administered as BiPAP) for at least 2 months
  5. Currently using NIPPV ≥5 days a week with an EPAP = 4 cm H2O.

Exclusion Criteria:

  1. Any medical condition that will interfere with participation
  2. Inability to consent for him/herself
  3. Known obstructive sleep apnea or obstructive pulmonary disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01154283

Locations
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
Kirsten Gruis
ALS Association
Investigators
Principal Investigator: Kirsten Gruis, MD University of Michigan
  More Information

No publications provided

Responsible Party: Kirsten Gruis, Associate Professor, University of Michigan
ClinicalTrials.gov Identifier: NCT01154283     History of Changes
Other Study ID Numbers: ALSA-9611
Study First Received: June 29, 2010
Last Updated: July 9, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Sclerosis
Central Nervous System Diseases
Metabolic Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Proteostasis Deficiencies
Spinal Cord Diseases
TDP-43 Proteinopathies

ClinicalTrials.gov processed this record on November 27, 2014